3D medical animation still shot, showing the structure of the coronavirus. Credit: Scientific Animations.

Enzo Biochem has introduced Covid-19 test kits under the US FDA’s emergency use authorisation (EUA) authority.

The tests were introduced as part of the company’s comprehensive Covid-19 programme.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Enzo Biochem Covid-19 test kits include a collection system, sample preparation, sample processing and detection products, as well as molecular analytic capabilities.

Additionally, the company said that the test uses in-house diagnostics technology to improve scale, throughput and sensitivity along with more relevant positive control materials.

RNAseP, Enzo’s control, confirms the presence of human mucosa cells in the specimen. This ensures accurate collections.

Enzo CEO Dr Elazar Rabbani said: “Enzo is uniquely positioned to address the Covid-19 pandemic from multiple angles. We have an open molecular diagnostic system with complete capabilities from sample collection to processing, detection and analytics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our open system allows for adaptability with regards to reagents, supplies and instruments. This system can be used for the current Covid-19 crisis, and furthermore, it can be repurposed for any current or future infectious agent diagnosis.

“Our solutions are available as full system product sales or as individual components.”

Overall, the company’s comprehensive Covid- 19 Program includes its molecular diagnostic virus screening products, IgG / IgM serological ELISA products to determine immunity and ELISA platform to detect inflammation.

The programme also features a proprietary drug candidate (SK1-I).

With the test, Enzo Biochem seeks to address the current challenges faced by the healthcare industry, including supply shortages.

In the US, there are more than 869,000 confirmed cases of coronavirus. Globally, the number has reached 2.7 million.